Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06501443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

LATAM LOWERS LDL-C

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 500 to 520 Site details revised at 5 of 11 sitesv6 Show 1 more changeShow less
    • Site details revised at 5 of 11 sites
  2. Study sites: 4 to 11v5
  3. Enrollment target: 520 to 500v4
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4 · Primary completion date: Nov 29, 2026 to Nov 27, 2026 · Start date changed from estimate of Jan 17, 2025 to Feb 11, 2025v3 Show 3 more changesShow less
    • Study sites: 0 to 4
    • Primary completion date: Nov 29, 2026 to Nov 27, 2026
    • Start date changed from estimate of Jan 17, 2025 to Feb 11, 2025
  5. Start date: Nov 29, 2024 to Jan 17, 2025v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and healthcare resource utilization in an in-hospital population of patients, admitted during the acute setting, stabilized and before discharge, following an acute cardiovascular event.
Trial Details
NCT Number NCT06501443
Lead Sponsor Novartis Pharmaceuticals
Conditions Hypercholesterolaemia
Enrollment 520 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov